Q1 2025 Aurobindo Pharma Ltd Earnings Call Transcript
Key Points
- Aurobindo Pharma Ltd (BOM:524804) reported a year-on-year growth of 10% in Q1 FY25, amounting to INR7,567 crores.
- The company's EBITDA margin remained stable at 21.4%, supported by stable raw material prices and incremental plant utilization.
- Net profit for the quarter increased by 61% year-on-year to INR919 crores.
- The Europe market demonstrated strong performance with revenue of EUR221 million and is on track to achieve EUR880 million plus for FY25.
- The company completed its first-ever buyback of INR750 crores, providing a tax-efficient return to shareholders.
- Higher operating expenses from newly commercialized plants and nonrecurring expenses, including remediation, reduced EBITDA and PBT by more than INR100 crores.
- The US market recorded revenues of USD426 million, marginally impacted by seasonality.
- The injectable and specialty business in the US faced supply constraints due to remediation actions, impacting revenue.
- The company incurred remediation costs of $9 million in Q1 FY25, which is expected to reduce to $2 million in Q2.
- The Pen-G plant faced teething problems, delaying significant revenue contributions until the next quarter.
Welcome to Aurobindo Pharma Q1 FY25 earnings call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to management for opening remarks. Thank you, and over to you, sir.
Thank you, Vandit. Good morning and a warm welcome to our first quarter FY25 earnings call. I am Shriniwas Dange from the Investor Relations team. We hope you have received the Q1 FY25 financials and the press release that was sent out on Saturday. These are also available on our website.
I would now like to introduce my senior management team on the call with us today represented by Dr. Satakarni Makkapat, CEO of Aurobindo Biosimilars, Vaccines and Peptide businesses, and Director, Aurobindo Pharma Limited; Mr. Yugandhar Puvvala, CEO of Eugia pharma Specialities Limited; Mr. Swami Iyer, CEO, Aurobindo Pharma USA; Mr. V. Muralidharan, CEO, Europe Formulations Businessand; and Mr. S Subramanian, CFO. We will begin the call with the summary highlights from the management
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
